On the other hand, Sfairopoulos et al. conducted a meta-analysis of a total 19 randomized control trials that enrolled 55,590 patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease for evaluating the effect of SGLT2 inhibitors on SCD (45). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.